TII
Work is underway to build a quantum computer in Abu Dhabi, in the United Arab Emirates, ushering an important milestone for the region in this breakthrough era in computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005788/en/
Technology Innovation Institute (TII), the dedicated ‘applied research’ pillar of Abu Dhabi’s newly established Advanced Technology Research Council (ATRC), today announced that its Quantum Research Centre (QRC) team led by its Chief Researcher Professor José Ignacio Latorre, will construct the quantum computer in the UAE capital, in collaboration with Barcelona-based Qilimanjaro Quantum Tech researchers.
“We are at the cusp of a new era with the advent of quantum computing,” H.E. Faisal Al Bannai, Secretary General of ATRC, said. “We are proud to embark on building one of these wonderful machines which will help us in various fields, from discovering new medicines to making new materials to designing better batteries to various Artificial Intelligence applications.”
A quantum computer uses quantum mechanics phenomena such as ‘superposition’ and ‘entanglement’ to generate and manipulate subatomic particles like electrons or photons - quantum bits also known as ‘qubits’ - to create exponentially stronger processing powers that can help perform complex calculations that would take much longer to solve even by the world’s most powerful classical supercomputers.
Prof. Latorre explained that preparatory work has already begun. “The first step in the process is to build a laboratory, equip it and complete installation of the cleanroom equipment, all of which is on track. Once done, the first qubits will be prepared, characterised and benchmarked. We expect the first simple quantum chips ‘Made in Abu Dhabi’ should come by the end of the summer,” he said.
Prof. Latorre said there are several technologies to construct quantum computers such as superconducting qubits, ion traps, optical qubits, and spin dots, adding QRC has opted to use superconducting qubits, which is the same technology that Google and IBM use in building their own quantum computers, and they offer the best qubit technology to scale to a larger quantum computer.
QRC is one of seven dedicated research centres at Technology Innovation Institute (TII).
About Technology Innovation Institute (TII)
Technology Innovation Institute (TII) is the dedicated ‘applied research’ pillar of Advanced Technology Research Council (ATRC). TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation.
For more information, visit www.tii.ae
Connect with us on social media:
LinkedIn: https://www.linkedin.com/company/tiiuae/
Twitter: https://twitter.com/TIIuae
Instagram: https://www.instagram.com/tiiuae/
About Quantum Research Centre (QRC)
Quantum Research Centre – at Technology Innovation Institute (TII) – has been created to develop world-class quantum-theoretical and experimental research by building and operating a quantum computer in the MENA region while advancing quantum communications and quantum sensors. The Centre aims to develop pioneering technologies backed by the expertise of an international team of leading researchers, dedicated to achieving a ‘Quantum Advantage’ which will transform the power and scope of computers. For more information, visit https://quantum.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005788/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom